EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Circular RNA-AnnexinA7 accelerates cisplatin resistance in non-small cell lung cancer via modulating microRNA-545-3p to mediate Cyclin D1

Jian Yao, Hai Yang Zhang, Shuang Gu, Jin Long Zou, Qiang Zhang, Ri Chu Qu

Acta Biochimica Polonica · 2023

DOI: 10.18388/abp.2020_6539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biochimica Polonica, 2023. Verfasst von Jian Yao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Jilin Provincial People's Hospital, Changchun City, Jilin Province, 130021, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, MicroRNAs. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To explore the mechanism of circular RNA (circRNA)-AnnexinA7 (ANXA7) in non-small cell lung cancer (NSCLC) cisplatin (DDP) resistance through microRNA (miR)-545-3p to target Cyclin D1 (CCND1).

Methods

DDP-resistant and non-resistant NSCLC tissues and normal tissues were collected. DDP-resistant cells (A549/DDP and H460/DDP) were constructed. circ-ANXA7, miR-545-3p, CCND1, P-Glycoprotein, and glutathione S-transferase-π in tissues and cells were measured. Analysis of circ-ANXA7 ring structure was performed, as well as detection of circ-ANXA7 distribution in cells. Cell proliferation was detected by MTT and colony formation assay, apoptosis rate was detected by flow cytometry, and cell migration and invasion were evaluated by Transwell assay. The targeting relationship between circ-ANXA7, miR-545-3p and CCND1 was verified. Measurement of tumor volume and quality in mice was performed.

Results

Circ-ANXA7 and CCND1 were elevated, while miR-545-3p was suppressed in DDP-resistant NSCLC tissues and cells. Circ-ANXA7 combined with miR-545-3p, which targeted CCND1 to expedite A549/DDP cell proliferation, migration, invasion, DDP resistance, but inhibited cell apoptosis.

Conclusion

Circ-ANXA7 enhances DDP resistance in NSCLC via absorbing miR-545-3p to target CCND1 and might be a latent therapeutic target for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMicroRNAsAnimalsMiceCyclin D1RNA, CircularCisplatinCell ProliferationDrug Resistance, NeoplasmCell Line, Tumor

Substanzen

Cyclin D1RNA, CircularCisplatinMicroRNAs

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Jilin Provincial People's Hospital, Changchun City, Jilin Province, 130021, China.

Zitieren

APA

Yao, J., Zhang, H. Y., Gu, S., Zou, J. L., Zhang, Q., & Qu, R. C. (2023). Circular RNA-AnnexinA7 accelerates cisplatin resistance in non-small cell lung cancer via modulating microRNA-545-3p to mediate Cyclin D1. Acta Biochimica Polonica. https://doi.org/10.18388/abp.2020_6539

Vancouver

Yao J, Zhang HY, Gu S, Zou JL, Zhang Q, Qu RC. Circular RNA-AnnexinA7 accelerates cisplatin resistance in non-small cell lung cancer via modulating microRNA-545-3p to mediate Cyclin D1. Acta Biochimica Polonica. 2023. doi:10.18388/abp.2020_6539

BibTeX
@article{Yao2023,
  author = {Yao, Jian and Zhang, Hai Yang and Gu, Shuang and Zou, Jin Long and Zhang, Qiang and Qu, Ri Chu},
  title = {Circular RNA-AnnexinA7 accelerates cisplatin resistance in non-small cell lung cancer via modulating microRNA-545-3p to mediate Cyclin D1},
  journal = {Acta Biochimica Polonica},
  year = {2023},
  doi = {10.18388/abp.2020_6539}
}
Kostenlos starten →